secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001628280-26-001386
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028
--------------------------------------------------------------------------------

- Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.
- Cash and cash equivalents ~$261M as of Dec 31, 2025; expected cash runway at least to 2028.
- LOTIS-7 Phase 1b shows 89.8% ORR and 77.6% CR; enrollment completion expected H1 2026.
- LOTIS-5 Phase 3 topline data expected in Q2 2026; potential sBLA and approval mid-2027 if positive.
- IND-enabling activities completed for PSMA-targeting ADC; partnership opportunities being explored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828026001386/0001628280-26-001386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828026001386/adc-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer